Dr. McNally currently is the President and CEO of GeoVax, Inc., a Smyrna, Georgia, clinical stage biotechnology company specializing in the development of vaccines to protect against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa), Zika virus, Malaria, chronic Hepatitis B infections and MUC1-positive cancer types. Prior to GeoVax, he co-founded and served as President of Cell Dynamics, a local company providing FDA regulated human tissue and cell processing services for research, pharmaceuticals and cell therapy. In 1984, Dr. McNally, co-founded CryoLife, Inc., a Kennesaw based company revolutionizing the use of human tissue. His name is associated with the patents for cryopreserved human heart valves, veins, arteries and components of the human knee used for reconstruction and transplant. During his association with CryoLife, the company went public on the New York Stock Exchange and became a recognized world leader in tissue transplant technology.
He is a Fellow of the American Institute of Medical and Biological Engineers; chairs the advisory board for the Georgia Tech Petit Institute for Bioengineering and Bioscience, and is a member of the advisory boards for Schiller College of Management at Tech and Villanova University entrepreneurial commercialization programs. He also serves as a member of the Kennesaw State advisory board for the College of Science and Mathematics. He is a current member of the board and the Past Chairman of Georgia BIO, the state association for healthcare technology, and is the 2005 recipient of their Biomedical Industry Growth Award.
Dr. McNally is an electrical engineering graduate from Villanova University and has a Ph.D. in Biomedical Engineering from the University of Pennsylvania. His career of mixed science and business has spanned 36 years.